Serum levels of advanced glycation end products in poorly metabolically controlled children with diabetes mellitus: Relation to HbA1c

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 14, Issue 4, 2001, Pages 207-211

  Jakus V ^a   Bauerova K ^a   Michalkova D ^a   Carsky J ^a  

^a UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

Children; Diabetes mellitus; HbA1c; Microangiopathy; Serum advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C;

ADOLESCENT; ADULT; AGE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DIABETES CONTROL; DIABETIC MICROANGIOPATHY; DISEASE DURATION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; MICROVASCULARIZATION; MONITORING; PREPUBERTY; PRIORITY JOURNAL; PUBERTY; RISK; SCHOOL CHILD; URINARY EXCRETION;

ADOLESCENT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; SPECTROMETRY, FLUORESCENCE;

EID: 0034757306     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications
2. Biochemical markers of diabetic microangiopathy. Past, present and future
3. Microalbuminuria and nephropathy in childhood diabetes
4. Diabetic nephropathy in children and adolescents: A critical review with particular reference to angiotensin-converting enzyme inhibitors
5. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
6. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes
7. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus
8. Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM
9. Advanced glycation end products in children and adolescents with diabetes: Relation to glycemic control and early microvascular complications
10. Advanced glycation end products in adolescents and young adults with diabetic angiopathy
11. Classification of diabetes mellitus and other categories of glucose intolerance
12. Inhibition of nonenzymatic protein glycation and lipid peroxidation by drugs with antioxidant activity
13. 1c by "high performance" cation exchange chromatography
14. 1c as indicator of metabolic compensation at children with diabetes mellitus
15. Fructosamine: A new approach to the estimation of serum glycosylation. An index of diabetic control
16. New developments in type 1 (insulin-dependent) diabetes
17. Carbonyl stress in the pathogenesis of diabetic nephropathy
18. Biology of disease. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging
19. Advanced glycosylation end products in diabetic renal and vascular disease
20. The role of free radicals, oxidative stress and antioxidant systems in diabetic vascular disease
21. The missing link: A single unifying mechanism for diabetic complications
22. Perspectives in diabetes. Role of oxidative stress in diabetic complications. A new perspective on an old paradigm
23. Oxidative stress and diabetic vascular complications
24. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents
25. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
26. The role of oxidative stress and NF-kappaB activation in late diabetic complications
27. 1c results in type 1 diabetes
28. Is glycohemoglobin testing useful in diabetes mellitus? Lessons from the diabetes control and complications trial
29. Fructosamine and glycated hemoglobin in the assessment of long term glycaemic control in diabetes
30. Comparison of serum fructosamine vs. glycohemoglobin as measures of glycemic control in a large diabetic population